Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0084 and Trastuzumab in HER2-Positive Breast Cancer Brain Metastases
NCT03765983Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paxalisib in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Feb 2019; status: terminated.
02
Drugs
paxalisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03765983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765983.